Actively Recruiting
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Led by Canwell Biotech Limited · Updated on 2024-10-31
71
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic Advanced Solid Tumors who have exhausted options for standard of care therapy.
CONDITIONS
Official Title
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent and comply with study requirements
- Male or female age 18 years or older at screening
- Histologically and cytologically confirmed locally advanced or metastatic solid tumors refractory or intolerant to standard therapies or without standard therapy
- Metastatic or locally advanced solid tumor progressed on, refractory to, or with no efficacious standard therapy; preferred tumor types include skin carcinoma, melanoma, Merkel cell carcinoma, breast cancer, head and neck squamous cell carcinoma, sarcoma, cervical carcinoma, and colorectal cancer
- Performance status of 0-1 on the ECOG Performance Scale
You will not qualify if you...
- Unresolved toxicities from prior therapy not resolved to CTCAE v5.0 Grade 0 or 1 except endocrinopathies, alopecia, and vitiligo
- Treatment with systemic corticosteroids exceeding 10 mg/day prednisone or equivalent
- Active infection requiring systemic therapy
- Unstable or inadequate cardiac function including NYHA Class 3 or 4 heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, important cardiac arrhythmias, or QTc interval >450 msec (male) or >470 msec (female)
- History of interstitial lung disease
- History of coagulopathy causing uncontrolled bleeding or other bleeding disorders
- Participation in another investigational agent clinical study within 30 days of screening
- Known psychiatric, substance abuse, or other disorders interfering with study cooperation
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen University Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China, 510535
Actively Recruiting
Research Team
H
Herui Yao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here